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Frequent mismatch-repair defects link
prostate cancer to Lynch syndrome
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Abstract
Background: A possible role for prostate cancer in Lynch syndrome has been debated based on observations of
mismatch-repair defective tumors and reports of an increased risk of prostate cancer in mutation carriers. Potential
inclusion of prostate cancer in the Lynch syndrome tumor spectrum is relevant for family classification, risk
estimates and surveillance recommendations in mutation carriers.
Methods: We used the population-based Danish HNPCC-register to identify all prostate cancers that developed in
mutation carriers and in their first-degree relatives from 288 Lynch syndrome families. The tumors were evaluated for
clinicopathologic features and mismatch-repair status, and the cumulative risk of prostate cancer was determined.
Results: In total, 28 prostate cancers developed in 16 mutation carriers and in 12 first-degree relatives at a median age
of 63 years. The majority of the tumors were high-grade tumors with Gleason scores 8–10. Prostate cancer was
associated with mutations in MSH2, MLH1 and MSH6 with loss of the respective mismatch repair protein in 69 % of the
tumors, though a MSI-high phenotype was restricted to 13 % of the tumors. The cumulative risk of prostate cancer at
age 70 was 3.7 % (95 % CI: 2.3–4.9).
Conclusion: We provide evidence to link prostate cancer to Lynch syndrome through demonstration of MMR
defective tumors and an increased risk of the disease, which suggests that prostate cancer should be considered in the
diagnostic work-up of Lynch syndrome.
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Background
Lynch syndrome is a multi-tumor syndrome with the
highest risks for colorectal cancer and endometrial cancer
though a number of other tumor types, e.g. cancer of the
urinary tract, the small bowel and the ventricle, ovarian
cancer, brain tumors and skin tumors develop at increased
incidence [1, 2]. Other tumor types assumed to represent
sporadic tumors in families with hereditary cancer, e.g.
breast cancer, pancreatic cancer and sarcoma may indeed
develop as part of the syndrome. This is suggested based
on identification of mismatch repair (MMR) defective tu-
mors of these subtypes and demonstration of an increased
risk of these tumor types in mutation carriers [3–10].
Prostate cancer is the most common tumor type in
men in the Western world with an estimated lifetime
risk of 18 % and a median age at diagnosis of 67 years
[1]. Worldwide, prostate cancer is the sixth common
tumor with more than 250,000 deaths annually [11]. In
Denmark, prostate cancer constitutes 23 % of all male
cancers with an estimated risk of 10 % for disease devel-
opment before age 75 [12]. The role of prostate cancer
in Lynch syndrome is unresolved though molecular in-
vestigations and epidemiologic studies have suggested a
potential link to the syndrome [1, 8, 13]. The MMR
system has been suggested to influence prostate carcino-
genesis e.g. through an increased risk of prostate cancer
linked to single nucleotide polymorphisms in MLH1 and
MSH3, and a role for complex structural rearrangements
in MSH2 and MSH6 as a mechanism underlying the
hypermutation in aggressive prostate cancer [14–20].
We assessed the role of prostate cancer in the Danish
Lynch syndrome cohort with characterization of MMR
status and risk estimates.
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Methods
Patients and tumor samples
The Danish Hereditary Non-Polyposis Colorectal Cancer
(HNPCC) Register is a national Danish register containing
all families identified with proven or suspected hereditary
cancer. Through research collaborations, data from the
register is freely available. We obtained data on all adeno-
carcinomas of the prostate that had developed in carriers
of a disease-predisposing MMR gene mutation in MLH1,
MSH2, MSH6 or PMS2 and in their first-degree relatives.
Clinical data were obtained from pathology reports and
clinical files. All patients provided an informed consent
for inclusion into the Danish HNPCC register during gen-
etic counseling sessions. Ethical approval for the study
was granted from the Ethical Committee at The Capital
Region of Copenhagen, Denmark (H-D-2007–0032).
All tumor specimens available were collected for ana-
lysis of MMR status. The tumors were pathologically
reviewed regarding their Gleason scores and the pres-
ence of tumor-infiltrating lymphocytes (TIL) (cut-off
≥4 per high-power field) [8, 21] by a pathologist (PJ),
who was blinded to MMR status.
Immunohistochemistry and analysis of microsatellite
instability
All tumors were immunohistochemically stained for the
MMR proteins MLH1, PMS2, MSH2 and MSH6. Briefly,
4-μm sections were placed on SuperFrost® Plus micro-
scope slides. Antigen retrieval was performed in a pressure
boiler in Target Retrieval Solution, pH 9 (Dako, Glostrup,
Denmark) and stained in an automated immunostainer
(Autostainer Plus, Dako, Glostrup, Denmark) using Dako
EnVision™FLEX+ Detection System, Peroxidase/DAB,
Rabbit/Mouse (Dako, Glostrup, Denmark), according to
the manufacturers' instructions. The antibodies used were
MLH1, clone ES05 (Dako, Glostrup, Denmark, dilution
1:100), PMS2, clone A16-4 (BD Pharmingen, San Diego,
CA, dilution 1:300), MSH2, clone FE11 (Calbiochem,
Merck KgaA, Darmstadt, Germany, dilution 1:100), and
MSH6, clone EPR3945 (Epitomics, Burlingame, dilution
1:100). Tumor MMR protein expression was assessed as
retained (normal), lost, or reduced (i.e. tumor cell staining
intensity was reduced compared with that of the normal
internal control).
For analysis of microsatellite instability (MSI), non-
necrotic tumor areas were macro-dissected from the
paraffin-embedded tumor blocks. DNA extraction was per-
formed from three 5-mm sections using the Qiagen FFPE
Kit (Qiagen Valencia, CA) according to the manufacturer’s
instructions. DNA concentration was determined using a
Qubit Fluorometric Quantitation (Invitrogen) and the
products run on a 3130XL Genetic Analyzer (Applied
Biosystems, Foster City, CA). The analysis was performed
using the MSI Analysis System, Version 1.2 (Promega,
Madison, WI) and included the 5 mononucleotide markers
BAT-25 BAT-26, NR-21, NR-24, and MONO-27 (Promega,
MSI Analysis System, Version 1.2, Madison, WI). The re-
sults were evaluated using GeneMapper Software Version
4.0 (Applied Biosystems, Foster City, CA) and defined as
MSI high when ≥2 markers were unstable, MSI low when
one marker was unstable and MSS when none of the
markers were unstable.
Statistical analysis
Genotypic and phenotypic data from all mutation car-
riers and their first-degree relatives were transferred into
R i386 3.1.0 (R: A Language and Environment for Statis-
tical Computing, 2011, R Foundation for Statistical
Computing, Vienna, Austria). EPCAM mutations (iden-
tified in one family) were pooled together with MSH2
mutations, while 7 PMS2 mutation families (none of
which contained any prostate cancers) were excluded
from the analyses. Mutation carriers were weighted by 1
and first-degree relatives by 0.5 motivated by a 50 % risk
of carrying the inherited mutation. The event times used
were age at diagnosis, age at death or current age
(censored at May 14, 2014). Cumulative incidences were
calculated with death as a competing risk (cmprsk: Sub-
distribution Analysis of Competing Risks, 2011, Bob
Gray, R package version 2.2-2). Confidence intervals
were calculated at age 70 using a non-parametric boot-
strap. Permutation tests with 10,000 replicates were used
to calculate p-values with significance set at p < 0.05.
Results
In total, 288 Lynch syndrome families with disease-
predisposing germline mutations in MLH1, MSH2,
MSH6 or PMS2 were identified in the Danish HNPCC
register. In this cohort of 1609 males (677 mutation
carriers and 932 first-degree relatives), prostate cancer
developed in 16 mutation carriers and in 12 first-degree
relatives. The median age at diagnosis of prostate cancer
was 61 (range 52–78) years for the mutation carriers
and 63 (range 53–81) years for the first-degree relatives.
All tumors were adenocarcinomas with Gleason scores
between 6 and 10. The tumors were linked to disease-
predisposing mutations in MSH2 (n = 14), MLH1 (n = 8)
and MSH6 (n = 6) (Table 1). Among the 28 men diag-
nosed with prostate cancer, 16 had a previous cancer
diagnosis, which included colon cancer in 15 cases. Four
prostate cancers had developed among the 593 male
non-mutation carriers (0.67 %) compared to 2.22 % of
the mutation carriers and 1.39 % of the first-degree
relatives.
Tumor tissue could be retrieved for MMR analysis
from 16 tumors (derived from 10 mutation carriers and
6 first-degree relatives), with loss of expression for the
respective MMR proteins in 11/16 tumors (including 7/
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10 tumors from mutation carriers (Table 1). Notably,
MMR protein loss was detected in all MSH2 and MSH6
associated tumors prostate cancers. MSI analysis applied
standard diagnostic markers and revealed a MSI-high
phenotype in 2 tumors, a MSI-low phenotype in 6 tu-
mors and a MSS phenotype in 8 tumors (Table 1, Fig. 1).
Notably, all MLH1-associated tumors has a microsatel-
lite stable phenotype. Pathologic review revealed TIL in
12/16 tumors, including all MMR defective tumors.
Gleason scores tended to be high in MMR defective
prostate cancer with Gleason scores of 8–10 in 7/11
MMR defective prostate cancers (Table 1).
Risk analysis could be performed based on 1488/1609
males from whom complete data were available. The cu-
mulative risk for prostate cancers at age 70 was 3.7 %
(95 % CI: 2.32–4.92) in mutation carriers and first-
degree relatives compared to 593 for non-mutation
carriers in these families (Fig. 2a). No significant differ-
ences could be demonstrated in relation to disease-
predisposing gene; MLH1 4.4 % (95 % CI: 1.44; 7.04),
MSH2 3.9 % (95 % CI: 1.96–5.70) and MSH6 2.5 %
(95 % CI: 0.56–4.12) (Fig. 2b).
Discussion
In the Danish Lynch syndrome cohort, 28 prostate can-
cers were identified. These tumors were diagnosed at a
median age of 63 years, which is in line with reports of
prostate cancers diagnosed at median 59–65 years in
Lynch syndrome [9, 22–26]. MMR protein loss in line
with the underlying MMR gene mutation was identified in









MMR gene mutation Immunohistochemical staining MSI
MLH1 PMS2 MSH2 MSH6
P32 Carrier 56 9 (4 + 5) NA MSH2 c.(?_-68)_366 + ?del NA
P7 Carrier 53 8 (4 + 4) y MSH2 c.560G > T + + − − MSI-L
P14 FDR 63 9 (5 + 4) y MSH2 c.646-?_1276 + ?del + + − − MSI-L
P8 Carrier 69 9 (4 + 5) y MSH2 c.892C > T + + − − MSI-L
P33 FDR 77 NA NA MSH2 c. 942 + 3A > T NA
P34 FDR 62 NA NA MSH2 c. 942 + 3A > T NA
P5 Carrier 69 8 (3 + 5) NA MSH2 c. 942 + 3A > T NA
P31 FDR 56 10 (5 + 5) NA MSH2 c. 942 + 3A > T NA
P10 Carrier 76 7 (4 + 3) y MSH2 c.1786_788delAAT + + − − MSI-L
P20 FDR 81 10 (5 + 5) y MSH2 c.1786_788delAAT + + − − MSI-H
P9 Carrier 52 8 (4 + 4) y MSH2 c.1906G > C + + − − MSS
P30 Carrier 60 NA NA MSH2 c.2038C > T NA
P12 Carrier 57 6 (3 + 3) y MSH2 c.2347delC + + − − MSI-H
P35 Carrier 67 NA NA MLH1 c. 350C > T NA
P11 Carrie 63 7 (4 + 3) n MLH1 c.588 + 5G > A + + + + MSS
P22 FDR 56 7 (3 + 4) y MLH1 c.1537_1547delInsC − − + + MSS
P2 Carrier 60 8 (4 + 4) n MLH1 c.1667 + 2delTAAATCAinsATTT + + + + MSS
P13 FDR 63 9 (4 + 5) y MLH1 c.1667 + 2delTAAATCAinsATTT − − + + MSI-L
P18 FDR 63 7 (3 + 4) y MLH1 c.1667 + 2delTAAATCAinsATTT + + + + MSS
P6 FDR 80 7 (3 + 4) n MLH1 c.1732-2A > T + + + + MSS
P1 Carrier 72 NA NA MLH1 c.1732-2A > T NA
P16 Carrier 74 10 (5 + 5) n MLH1 c.1852_54delAAG + + + + MSS
P37 Carrier 58 NA NA MSH6 C.1444C > T NA
P3 Carrier 58 8 (4 + 4) y MSH6 c.1483C > T + + − − MSI-L
P15 Carrier 78 6 (3 + 3) y MSH6 c.3647-1G > A + + + − MSS
P38 FDR 81 NA NA MSH6 c. 3609_3612delTGCA NA
P36 FDR 53 NA NA MSH6 c.3992 + 1 T > C NA
P17 FDR 57 7 (3 + 4) NA MSH6 c.3992 + 1 T > C NA
Abbreviations: FDR first-degree relatives, HPF high-power field, MMR mismatch repair, MSI microsatellite instability high/low, MSS microsatellite stability, n no, TIL
tumour-infiltrating lymphocytes, y yes, NA Not available
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11/16 prostate cancers, including all MSH2 and MSH6
mutant tumors and supports observations of a high de-
gree, 69–100 %, of MMR deficiency in prostate cancers in
Lynch syndrome [8, 24, 27]. MSH2 mutations were found
in 14/28 prostate cancers and this MMR gene has been
linked to an expanded spectrum of extracolonic tumors
Fig. 1 a A prostate cancer from an individual with a MSH2 mutation showing normal expression for MLH1 and PMS2 (A and B) and loss of
expression for MSH2 and MSH6 (C and D); b microsatellite instability for the markers BAT-26, NR-21, BAT-25, NR-24 and MONO-27 in the same
prostate cancer
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with an increased risk for e.g. urothelial cancer, brain tu-
mors and skin tumors [6, 8–10, 22–24, 28, 29]. A MSI-
high phenotypes was identified only in 2 prostate cancers
using a standard MSI markers panel with an additional
number of tumors showing a MSI-low phenotype. This
observation supports an earlier report of MSI defects in
4–10 % of Lynch syndrome associated prostate cancers
[30]. MSI phenotypes were predominantly observed in
MSH2 and MSH6 associated tumors and could poten-
tially reflect alternate mechanisms by which MSI is
acquired in prostate cancer or an association with
tumor differentiation [19] [31]. These observations
support a role for MMR defects in prostate carcino-
genesis and link germline MMR defects to the devel-
opment of prostate cancer.
MMR-defective tumors show histopathologic charac-
teristics that include poor differentiation and lympho-
cytic reactions with an increased number of TIL [8].
Blinded analysis of TIL showed a striking correlation
with MMR defects with TIL in all MMR defective pros-
tate cancer and in only 1/5 MSS and MMR proficient
prostate cancers. TIL has been suggested to represent an
adverse prognostic factor in prostate cancer [32–34]. Of
the 11 MMR defective prostate cancers in our study, 7
had a Gleason score of ≥8 suggesting aggressive tumors.
Hereditary prostate cancers, also associated with BRCA2
mutations, have been suggested to have an accelerated
tumor development an aggressive phenotype. Knowledge
about prostate cancer in Lynch syndrome is scarce, but
early age at onset, frequent TIL and an aggressive
Fig. 2 Non-parametric risk estimates showing a age-specific cumulative risks for prostate cancer; b mortality rates in MLH1, MSH2 and MSH6 families
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phenotype warrants further investigation related to a pos-
sible role for surveillance and potential therapeutic implica-
tions from e.g. immunotherapy with PD-1 inhibitors [35].
The cumulative risk of prostate cancer at age 70 was
3.7 % in mutation carriers. No significant differences
were discerned in relation to disease-predisposing gene,
but this analysis is based on very limited numbers.
Under the assumption that MMR-defective prostate can-
cer signifies Lynch syndrome, mutation carriers can be
estimated to be at a 2- to 3-fold increased risk of pros-
tate cancer compared to the general population [1, 13].
Growing data suggest that MMR defects in prostate can-
cer may signify chromoplexy, whereby a single hit infers
genetic complexity of relevance for prostate cancer initi-
ation, progression and therapeutics [18, 19].
Conclusions
The Danish Lynch syndrome cohort contains 28 prostate
cancers that developed at a median age of 63 years,
showed high Gleason scores and frequent TILs. The tu-
mors were predominantly linked to MSH2 mutations.
Frequent MMR defects consistent with the underlying
germline defects suggest that prostate cancer is included
in Lynch syndrome tumor spectrum and should be con-
sidered during genetic counseling.
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